Mr. Ahmad Doroudian reports

BETTERLIFE ANNOUNCES STOCK OPTION GRANT

Betterlife Pharma Inc. has granted an aggregate of 6.05 million options to purchase common shares to its directors, officers and employees. Each option is exercisable upon vesting to acquire one common share of the company at a price of 5.5 cents per share for a period of five years, with the options vesting in four equal tranches on the date of grant, and six-, 12- and 18-month anniversaries of the date of grant.

About Betterlife Pharma Inc.

Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling (investigational new drug) studies, is a non-hallucinogenic and non-controlled LSD derivative in development, and it is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

Betterlife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.